New Tor­rent Phar­ma­ceu­ti­cals Form 483 high­lights clean­ing and oth­er qual­i­ty is­sues

In­di­an drug­mak­er Tor­rent Phar­ma­ceu­ti­cals, which has pulled in about $1 bil­lion in 2022 rev­enue, is the lat­est In­di­an man­u­fac­tur­er to find it­self un­der the FDA’s mi­cro­scope.

A 15-page Form 483 in­spec­tion re­port fol­lowed an in­spec­tion from Sep­tem­ber that re­vealed three ob­ser­va­tions at its man­u­fac­tur­ing site in the vil­lage of In­drad, in the state of Gu­jarat in the na­tion’s east. Ac­cord­ing to the com­pa­ny, the site man­u­fac­tures tablets, cap­sules and vials.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER